Coronavirus vaccine: Oxford University and AstraZeneca vaccine has been approved for use in the UK

A Covid-19 vaccine from Oxford University and AstraZeneca has been approved for use in the UK, paving the way for mass rollout.
Watch more of our videos on Shots! 
and live on Freeview channel 276
Visit Shots! now

The jab, which has been described as a "game changer", was given the green light by the Medicines and Healthcare products Regulatory Agency (MHRA).

The UK has ordered 100 million doses of the vaccine - enough to vaccinate 50 million people.

Read More
Brexit: Scottish minister pledges to fight for seed potato exporters
Photo credit: Steve Parsons / PA WirePhoto credit: Steve Parsons / PA Wire
Photo credit: Steve Parsons / PA Wire
Hide Ad
Hide Ad

A Department of Health and Social Care spokesman said: "The Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca's Covid-19 vaccine for use.

"This follows rigorous clinical trials and a thorough analysis of the data by experts at the MHRA, which has concluded that the vaccine has met its strict standards of safety, quality and effectiveness."

Data published in The Lancet medical journal in early December showed the vaccine was 62% effective in preventing Covid-19 among a group of 4,440 people given two standard doses of the vaccine when compared with 4,455 people given a placebo drug.

Of 1,367 people given a half first dose of the vaccine followed by a full second dose, there was 90% protection against Covid-19 when compared with a control group of 1,374 people.

Hide Ad
Hide Ad

The overall Lancet data, which was peer-reviewed, set out full results from clinical trials of more than 20,000 people.

Among the people given the placebo drug, 10 were admitted to hospital with coronavirus, including two with severe Covid which resulted in one death.

But among those receiving the vaccine, there were no hospital admissions or severe cases.

The half dose followed by a full dose regime came about as a result of an accidental dosing error.

Hide Ad
Hide Ad

However, the MHRA was made aware of what happened and clinical trials for the vaccine were allowed to continue.

In an interview with the Sunday Times, AstraZeneca chief executive Pascal Soriot suggested that further data submitted to the regulator showed the vaccine could match the 95% efficacy achieved by the Pfizer/BioNTech and Moderna vaccines.

"We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else," he said.

A message from the Editor:Thank you for reading this article. We're more reliant on your support than ever as the shift in consumer habits brought about by Coronavirus impacts our advertisers.

If you haven't already, please consider supporting our trusted, fact-checked journalism by taking out a digital subscription.

Comment Guidelines

National World encourages reader discussion on our stories. User feedback, insights and back-and-forth exchanges add a rich layer of context to reporting. Please review our Community Guidelines before commenting.